BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
QuintilesIMS
Fuji
McKinsey
Citi
US Department of Justice
Queensland Health
Chubb
Cipla
Medtronic

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 074529

« Back to Dashboard

NDA 074529 describes ETOPOSIDE, which is a drug marketed by Mylan, Accord Hlthcare, Fresenius Kabi Usa, Hospira, Mylan Labs Ltd, Pharmachemie Bv, Pierre Fabre, Teva Parenteral, Teva Pharms Usa, Watson Labs, Watson Labs Inc, and West-ward Pharms Int, and is included in fourteen NDAs. It is available from six suppliers. Additional details are available on the ETOPOSIDE profile page.

The generic ingredient in ETOPOSIDE is etoposide. There are eleven drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the etoposide profile page.
Summary for 074529
Tradename:ETOPOSIDE
Applicant:Teva Pharms Usa
Ingredient:etoposide
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 074529
Mechanism of ActionTopoisomerase Inhibitors
Medical Subject Heading (MeSH) Categories for 074529
Suppliers and Packaging for NDA: 074529
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ETOPOSIDE etoposide INJECTABLE;INJECTION 074529 ANDA Teva Parenteral Medicines, Inc. 0703-5653 0703-5653-01 1 VIAL, MULTI-DOSE in 1 CARTON (0703-5653-01) > 5 mL in 1 VIAL, MULTI-DOSE
ETOPOSIDE etoposide INJECTABLE;INJECTION 074529 ANDA Teva Parenteral Medicines, Inc. 0703-5656 0703-5656-01 1 VIAL, MULTI-DOSE in 1 CARTON (0703-5656-01) > 25 mL in 1 VIAL, MULTI-DOSE

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength20MG/ML
Approval Date:Jul 24, 1996TE:APRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Daiichi Sankyo
Fuji
Healthtrust
Julphar
Federal Trade Commission
Accenture
Colorcon
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot